These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21186673)

  • 1. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
    Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
    Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Betriu C; Gómez M; López-Fabal F; Culebras E; Rodríguez-Avial I; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 2010 Sep; 29(9):1179-81. PubMed ID: 20521156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study.
    Gales AC; Azevedo HD; Cereda RF; Girardello R; Xavier DE;
    Braz J Infect Dis; 2011; 15(6):513-20. PubMed ID: 22218508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
    Wali N; Mirza IA
    J Coll Physicians Surg Pak; 2016 Apr; 26(4):297-301. PubMed ID: 27097701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
    Gimeno C; Cantón R; García A; Gobernado M;
    Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
    Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
    Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
    Esterly JS; Qi C; Malczynski M; Scheetz MH
    Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of
    Negi A; Anand M; Singh A; Kumar A; Sahu C; Prasad KN
    Indian J Crit Care Med; 2017 Oct; 21(10):703-706. PubMed ID: 29142383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.